Lipoprotein(a): Intrigues and insights

Current Opinion in Lipidology

Volumn 10, Issue 3, 1999, Pages 225-236

  Hobbs, Helen H ^a,b   White, Ann L ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A;

ATHEROGENESIS; ATHEROSCLEROSIS; BIOCHEMISTRY; GENE SEQUENCE; GENETICS; LIPOPROTEIN BLOOD LEVEL; METABOLISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RABBIT; REVIEW;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; APOLIPOPROTEINS; APOPROTEIN(A); ARTERIOSCLEROSIS; CLINICAL TRIALS; EVOLUTION; HUMANS; LIPOPROTEIN(A);

EID: 0032816711     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199906000-00005     Document Type: Review

References (152)

1. 1 Berg K. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand 1963; 59:369-382.
2. 2 Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes: Inheritance and relation to Lp(a) - lipoprotein concentrations in plasma. J Clin Invest 1987; 80:458-465.
3. 3 Albers JJ, Hazzard WR. Immunochemical quantification of human plasma Lp(a) lipoprotein. Lipids 1974; 9:15-26.
4. 4 Utermann G. Lipoprotein(a). In: The metabolic and molecular bases of inherited disease. Vol. II. Scriver CR et al (editors). New York: McGraw Hill, 1995.
5. 5 Malgaretti N, Acquati F, Magnaghi P, Bruno L, Pontoglio M, Rocchi M et al. Characterization by yeast artificial chromosome cloning of the linked apolipoprotein(a) and plasminogen genes and identification of the apolipoprotein(a) 5′ flanking region. Proc Natl Acad Sci USA 1992; 89:11584-11588.
6. 6 McLean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330:132-137.
7. 7 Morrisett JD, Gaubatz JW, Knapp RD, et al. (1990) Structural properties of apo(a): a major apoprotein of human lipoprotein(a). In: Lipoprotein (a). Scanu A (editor). San Diego: Academic Press Inc.; pp. 53-74.
8. 8 Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993; 2:933-940.
9. 9 van der Hoek YY, Wittekoek ME, Beisiegel U, Kastelein JJ, Koschinsky ML. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Hum Mol Genet 1993; 2:361-366.
10. 10 Albers JJ, Wahl P, Hazzard WR. Quantitative genetic studies of the human plasma Lp(a) lipoprotein. Biochem Genet 1974; 11:475-486.
11. 11 Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90:52-60.
12. 12 Boerwinkle E, Menzel HJ, Kraft HG, Utermann G. Contribution of Lp(a) glycoprotein phenotype to normal lipid variation. Hum Genet 1989; 8:73-78.
13. 13 Cohen JC, Chiesa G, Hobbs HH. Sequence polymorphisms in the apolipoprotein(a) gene. Evidence for dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels. J Clin Invest 1993; 91:1630-1636.
14. 14 Mooser V, Mancini FP, Boop S, Petho-Schramm AP, Guerra R, Boerwinkle E, et al. Sequence polymorphisms in the apo(a) gene associated with specific levels of Lp(a) in plasma. Hum Mol Genet 1995; 4:173-181.
15. 15 Mancini FP, Mooser V, Guerra R, Hobbs HH. Sequence microheterogeneity in apolipoprotein(a) gene repeats and the relationship to plasma Lp(a) levels. Hum Mol Genet 1995; 4:1535-1542.
16. 16 Puckey LH, Lawn RM, Knight BL. Polymorphisms in the apolipoprotein(a) gene and their relationship to allele size and plasma lipoprotein(a) concentration. Hum Mol Genet 1997; 6:1099-1107.
17. 17 Marcovina SM, Gaur VP, Albers JJ. Biological variability of cholesterol, triglyceride, low-and high-density lipoprotein cholesterol, lipoprotein(a), and apolipoprotein A-I and B Clin Chem 1994; 40:574-578.
18. 18 Guyton JR, Dahlèn GH, Patsch W, Kautz JA, Gotto AM Jr. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis 1985; 5:265-272.
19. 19 Mooser V, Scheer D, Marcovina SM, Wang J, Guerra R, Cohen JC, Hobbs HH. The apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African-Americans. Am J Hum Genet 1997; 61:401-417.
20. 20 Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Csàszàr A, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 1991; 86:607-614.
21. 21 Kraft HG, Menzel HJ, Hoppichler F, Vogel W, Utermann G. Changes of genetic apolipoprotein phenotypes caused by liver transplantation: Complications for apolipoprotein synthesis. J Clin Invest 1989; 83:137-142.
22. 22 Krempler F, Kostner GM, Bolzano K. Turnover of lipoprotein(a) in man. J Clin Invest 1980; 65:1483-1490.
23. 23 Rader DJ, Cain W, Zech LA, Usher D, Brewer HB Jr. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 1993; 91:443-447.
24. 24 Azrolan N, Gavish D, Breslow JL. Plasma lipoprotein(a) concentration is controlled by apolipoprotein(a) (apo(a)) protein size and the abundance of hepatic apo(a) mRNA in a cynomolgus monkey model. J Biol Chem 1991; 266:13866-13872.
25. 25 Hixson JE, Britten ML, Manis GS, Rainwater DL. Apolipoprotein(a) (apo(a)) glyco-protein isoforms result from size differences in apo(a) mRNA in baboons. J Biol Chem 1989; 264:6013-6016.
26. 26 Wade DP, Knight BK, Harders-Spengel K, Soutar AK. Detection and quantitation of apolipoprotein(a) mRNA in human liver and its relationship with plasma lipoprotein(a) concentration. Atherosclerosis 1991; 91:63-72.
27. 27 Wade DP, Clarke JG, Lindahl GE, Liu AC, Zysow BR, Meer K, Schwartz K, Lawn RM. 5′ control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. Proc Natl Acad Sci U S A 1993; 90:1369-1373.
28. 28 Wade DP, Lindahl GE, Lawn RM. Apolipoprotein(a) gene transcription is regulated by liver-enriched trans-acting factor hepatocyte nuclear factor 1 alpha. J Biol Chem 1994; 269:19757-19765.
29. 29 Wade DP, Puckey LH, Knight BL, Acquati F, Mihalich A, Taramelli R. Characterization of multiple enhancer regions upstream of the apolipoprotein(a) gene. J Biol Chem 1997; 272:30387-30399.
30. 30 Yang Z, Boffelli D, Boonmakr N, Schwartz N, Lawn R. Apolipoprotein(a) gene enhancer resides within a LINE element. J Biol Chem 1998; 273:891-897.
31. 31 Zysow BR, Lindahl GE, Wade DP, Knight BL, Lawn RM. C/T polymorphism in the 5′ untranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation. Arterioscler Thromb Vasc Biol 1995; 15:58-64.
32. 32 White AL, Hixson JE, Rainwater DL, Lanford RE. Molecular basis for 'null' lipoprotein(a) phenotypes and the influence of apolipoprotein(a) size on plasma lipoprotein(a) level in the baboon. J Biol Chem 1994; 269:9060-9066.
33. 33 White AL, Guerra B, Lanford RE. Influence of allelic variation on apolipoprotein(a) folding in the endoplasmic reticulum. J Biol Chem 1997; 272:5048-5055.
34. 34 White AL, Guerra B, Wang J, Lanford RE. Presecretory degradation of apolipoprotein(a) is mediated by the proteasome pathway. J Lipid Res 1999; 40:275-286.
35. 35 Cox JA, Jett C, Hixson JE. Molecular basis of an apolipoprotein(a) null allele: a splice site mutation is associated with deletion of a single exon. J Lipid Res 1998; 39:1319-1326.
36. 36 Frank S, Durovic S, Kostner GM. Structural requirements of apo(a) for the lipoprotein-a assembly. Biochem J 1994; 15:27-30.
37. 37 Bonen DK, Nassir F, Hausman AM, Davidson NO. Inhibition of N-linked glycosylation results in retention of intracellular apo(a) in hepatoma cells, although nonglycosylated and immature forms of apolipoprotein(a) are competent to associate with apolipoprotein B-100 in vitro. J Lipid Res 1998; 39:1629-1640.
38. 38 Chiesa G, Hobbs HH, Koschinsky ML, Lawn RM, Maika SD, Hammer RE. Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a). J Biol Chem 1992; 267:24369-24374.
39. 39 White AL, Rainwater DL, Lanford RE. Intracellular maturation of apolipoprotein(a) and assembly of lipoprotein(a) in primary baboon hepatocytes. J Lipid Res 1993; 34:509-517.
40. 40 Koschinsky ML, Cote GP, Gabel B, Van der Hoek YY. Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J Biol Chem 1993; 268:19819-19825.
41. 41 Wilkinson J, Munro LH, Higgins JA. Apolipoprotein (a) is not associated with apolipoprotein B in human liver. J Lipid Res 1994; 35:1896-1901.
42. 42 White AL, Lanford RE. Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J Biol Chem 1994; 269:28716-28723.
43. 4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci U S A 1993; 90:11643-11647.
44. 44 Ernst A, Helmhold M, Brunner C, Pethö-Schramm A, Armstrong VW, Müller H-J. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J Biol Chem 1995; 270:6227-6234.
45. 45 McCormick SP, Ng JK, Taylor S, Flynn LM, Hammer RE, Young SG. Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a). Proc Natl Acad Sci U S A 1995; 92:10147-10151.
46. 46 Callow MJ, Rubin EM. Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein(a) in vivo. J Biol Chem 1995; 270:23914-23917.
47. 47 Terada K, Manchikalapudi P, Noiva R, Jauregui HO, Stockert RJ, Schilsky ML. Secretion, surface localization, turnover, and steady state expression of protein disulfide isomerase in rat hepatocytes. J Biol Chem 1995; 270:20410-20416.
48. 3500-Gln). J Biol Chem 1994; 269:30320-30325.
49. 49 Steyrer E. Durovic S, Frank S, GieBauf W, Burger A, Dieplinger H, et al. The role of lecithin : cholesterol acyltransferase for lipoprotein(a) assembly. J Clin Invest 1994; 94:2330-2340.
50. 50 Su W, Campos H, Judge H, Walsh BW, Sacks FM. Metabolism of apo(a) and apoB100 of lipoprotein(a) in women: effect of postmenopausal estrogen replacement. J Clin Endocrinol Metab 1998; 83:3267-3276.
51. 51 Nassir F, Bonen DK, Davidson NO. Apolipoprotein(a) synthesis and secretion from hepatoma cells is coupled to triglycoride synthesis and secretion. J Biol Chem 1998; 273:17792-17800.
52. 52 Koschinsky ML, Tomlinson JE, Zioncheck TF, Schwartz K, Eaton DL, Lawn RM. Apolipoprotein(a): expression and characterization of a recombinant form of the protein in mammalian cells. Biochem 1991; 30:5044-5051.
53. 53 Gaw A, Boerwinkle E, Cohen J, Hobbs H. Comparative analysis of the apo(a) gene, apo(a) glycoprotein and plasma concentrations of Lp(a) in three ethnic groups evidence for no common null allele at the apo(a) locus. J Clin Invest 1994; 93:2526-2534.
54. 54 Ye S, Keling J, Stein O, Stein Y, McConathy WJ. Tissue distribution of [3H]cholesteryl linoeyl ether-labeled human Lp(a) in different rat organs. Biochim Biophys Acta 1988; 963:534-540.
55. 55 Knight BL, Perombelon YFP, Soutar AK, Wade DP, Seed M. Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects. Atherosclerosis 1991; 87:227-237.
56. 56 Rader DJ, Mann WA, Cain W, Kraft HG, Usher D, Zech LA, et al. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995; 95:1403-1408.
57. 57 Hofmann SL, Eaton DL, Brown MS, McConathy WJ, Goldstein JL, Hammer RE. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest 1990; 85:1542-1547.
58. 58 Argraves KM, Korzarsky KF, Fallon JT, Harpel PC, Strickland DK. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest 1997; 100:2170-2181.
59. 59 Sakai J, Hoshino A, Takahashi S, Miura Y, Ishii H, Suzuki H, et al. Structure, chromosome location, and expression of the human very low density lipoprotein receptor gene. J Biol Chem 1994; 269:2173-2182.
60. 60 Kronenberg F, Trenkwalder E, Lingenhel A, Friedrich G, Lhotta K, Schober M, et al. Renovascular arteriovenous differences in Lp(a) plasma concentrations suggest removal of Lp(a) from the renat circulation. J Lipid Res 1997; 38: 1755-1763.
61. 61 Parra HJ, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart J-C. Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987; 33:721.
62. 62 Sechi LA, Zingaro L, DeCarli S, Sechi G, Catena C, Falleti E, et al. Increased serum lipoprotein(a) levels in patients with early renal failure. Ann Intern Med 1998; 129:457-461.
63. 63 Oida K, Takai H, Maeda H, Takahashi S, Shimada A, Suzuki J, et al. Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. Clin Chem 1992; 38:2244-2248.
64. 64 Mooser V, Seabra MC, Abedin M, Landschulz KT, Marcovina S, Hobbs HH. Apo(a) kringle 4-containing fragments in human urine - relationship to plasma levels of lipoprotein(a). J Clin Invest 1996; 97:858-864.
65. 65 Edelstein C, Italia JA, Klezovitch O, Scanu AM. Functional and metabolic differences between elastase-generated fragments of human lipoprotein(a) and apolipoprotein(a). J Lipid Res 1996; 37:1786-1801.
66. 66 Scanu AM. Proteolytic modifications of lipoprotein(a): potential relevance to its postulated atherothrombogenic role. J Invest Med 1998; 46:359-363.
67. 67 Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest 1996; 98:2414-2424.
68. 68 Tato JR, Rifai N, Berg K, Couderc R, Dati F, Kostner GM, et al. International federation of clinical chemistry standardization project for the measurement of lipoprotein(a). Phase I. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators. Clin Chem 1998; 44:1629-1640.
69. 69 Berglund L. Diet and drug therapy for lipoprotein(a). Curr Opin Lipidol 1995; 6:48-56.
70. 70 Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H. Lipoprotein(a) in health disease. Crit Rev Clin Lab Sci 1996; 33:495-543.
71. 71 Djurovic S, Berg K. Epidemiology of Lp(a) lipoprotein: its role in atherosclerotic/thrombotic disease. Clin Genet 1997; 52:281-292.
72. 72 Stein JH, Rosenson RS. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 1997; 157:1170-1176.
73. 73 Heinrich J, Sandkamp M, Kokott R, Schulte H, Assmann G. Relationship of lipoprotein (a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem 1991; 37:1950-1954.
74. 74 Kim CJ, Min YK, Ryu WS, Kwak JW, Ryoo UH. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Arch Intern Med 1996; 156:1693-1700.
75. 75 Lingenhel A, Kraft HG, Kotze M, Peeters AV, Kronenberg F, Kruse R, Utermann G. Concentrations of the atherogenic Lp(a) are elevated in FH. Eur J Hum Genet 1998; 6:50-60.
76. 76 Perombelon YFN, Soutar AK, Knight BL. Variation in lipoprotein(a) concentration associated with different apolipoprotein(a) alleles. J Clin Invest 1994; 93:1481-1492.
77. 77 Knight BL. Lp(a) catabolism in hypercholesterolaemic individuals. Chem Phys Lipids 1994; 67/68:233-239.
78. 78 van der Hoek YY, Lingenhel A, Kraft HG, Defesche JC, Kastelein JJ, Utermann G. Sib-pair analysis detects elevated Lp(a) levels and large variation of Lp(a) concentration in subjects with familial defective apoB. J Clin Invest 1997; 99:2269-2273.
79. 79 Matsumoto K, Miyake S, Yano M, Ueki Y, Tominaga Y. Increase of lipoprotein(a) with troglitazone. Lancet 1997; 350:1748-1749.
80. 80 Velazquez EM, Mendoza G, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 1997; 46:454-457.
81. 81 Georgala S, Schulpis KH, Potouridou I, Papadogeorgaki H. Effects of isotretinoin therapy on lipoprotein(a) serum levels. Int J Derm 1997; 36:863-864.
82. 82 Ramharack R, Wyborski RJ, Spahr MA. The apolipoprotein(a) promoter contains a retinoid response element. Biochem Biophys Res Commun 1998; 245:194-197.
83. 83 Seed M, O'Connor B, Perombelon N. O'Donnell M, Reaveley D, Knight BL. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis 1993; 101:61-68.
84. 84 de Sain-Van der Velden MGM, Reijngoud D-J, Kaysen GA, Gadellaa MM, Voorbij H, Stellaard F, et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol 1998; 9:1474-1481.
85. 85 Frazer KA, Narla G, Zhang JL, Rubin EM. The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. Nature Genet 1995; 9:424-431.
86. 86 Acquati F, Hammer R, Ercoli B, Mooser V, Tao R, Ronicke V, et al. YAC transgenesis as a tool to study the regulation of a highly expressed apolipoprotein(a) allele. J Lipid Res 1999; in press.
87. 87 Ruixin T, Acquati F, Marcovina SM, Hobbs HH. Human growth hormone increases apolipoprotein(a) expression in transgenic mice. Arterioscler Thromb Vasc Biol 1999; in press.
88. 88 Zysow BR, Kauser K, Lawn RM, Rubanyi GM. Effects of estrus cycle, ovariectomy, and treatment with estrogen, tamoxifen, and progesterone on apolipoprotein(a) gene expression. Aterioscler Thromb Vasc Biol 1997; 17:1741-1745.
89. 89 Ribichini F, Steffenino G, Dellavalle A, Vado A, Ferrera V, Camilla T, et al. Plasma lipoprotein(a) is not a predictor for restenosis after elective high-pressure coronary stenting. Circulation 1998; 98:1172-1177.
90. 90 Rhoads GG, Dahlèn GH, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986; 256:2540-2544.
91. 91 Simons L, Friedlander Y, Simons J, McCallum J. Lipoprotein(a) is not associated with coronary heart disease in the elderly: cross-sectional data from the Dubbo study. Arteriosclerosis 1993; 99:87-95.
92. 92 Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis E, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. JAMA 1994; 271:999-1003.
93. 93 Cremer P, Nagel D, Mann H, Labrot B, Muller-Berninger R, Elster H, Seidel D. Ton-year follow-up results from the Goettingen risk, incidence and prevalence study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis 1997; 129:221-230.
94. 94 Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Weiland H et al. The association between serum l_p(a) concentrations and angiographically assessed coronary atherosclerosis: dependence on serum DL levels. Atherosclerosis 1986; 62:249-257.
95. 95 Hopkins PN, Hunt SC, Schreiner PJ, Eckfeld JH, Borecki IB, Ellison CR, et al. Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease: results from the NHLBI Family Heart Study. Atherosclerosis 1998; 141:333-345.
96. 96 Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci U S A 1992; 89:10193-10137.
97. 97 Sandhotzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, et al. Apo(a) isoforms predict risk for coronary heart disease. Arterioscler Thromb 1992; 12:1214-1226.
98. 98 Islam S, Gutin B, Smith C, Treiber F, Kamboh MI. Association of apolipoprotein(a) phenotypes in children with family history of premature coronary artery disease. Arterioscler Thromb 1994; 14:1609-1616.
99. 99 Marcovina SM, Albers JJ, Wijsman E, Zhang Z, Chapman NH, Kennedy H. Differences in Lp(a) concentrations and apo(a) polymorphs between Black and White Americans. J Lipid Res 1996; 37:2569-2585.
100. 100 Lewn R, Wade D, Hammer R, Verstuyft J, Rubin E. Atherogenesis in transgenic mice expressing human apolipoprotein (a). Nature 1992; 360:670-672.
101. 101 Callow MJ, Verstuyft J, Tangirala R, Palinski W, Rubin EM. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein(a). J Clin Invest 1995; 96:1639-1646.
102. 102 Mancini FP, Newland DL, Mooser V, Murata J, Marcovina S, Young SG, et al. Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta of mice. Arterioscler Thromb Vasc Biol 1995; 15:1911-1916.
103. 103 Linton MF, Farese RV, Chiesa G, Grass DS, Chin P, Hammer RE, et al. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J Clin Invest 1993; 93:3029-3037.
104. 104 Liu AC, Lawn RM, Verstuyft JG, Rubin EM. Human apolipoprotein A-1 prevents atherosclerosis associated with apolipoprotein(a) in transgenic mice. J Lipid Res 1994; 35:2263-2267.
105. 105 Boonmark NW, Lou XJ, Yang ZJ, Schwartz K, Zhang JL, Rubin EM, Lawn RM. Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest 1997; 1:558-564.
106. 106 Sanan DA, Newland DL, Tal R, Marcovina S, Wang J, Mooser V, et al. Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a). Proc Natl Acad Sci U S A 1998; 95:4544-4549.
107. 107 Rouy D, Duverger N, Lin SD, Emmanuel F, Houdebine L-M, Denefle P, et al. Apolipoprotein(a) yeast artificial chromosome transgenic rabbits. J Biol Chem 1998; 273:1247-1251.
108. 108 Rath M, Niendorf A, Reblin T, Dietel M, Krebber H-J, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989; 9:579-592.
109. 109 Ragab MS, Selvaraj P, Sgoutas DS. Oxidized lipoprotein(a) induces cell adhesion molecule Mac-1 (CD 11b) and enhances adhesion of the monocytic cell line U937 to cultured endothelial cells. Atherosclerosis 1996; 123:103-113.
110. 110 Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A 1989; 86:3847-3851.
111. 111 Jamieson DG, Usher DC, Rader DJ, Lavi E. Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. Am J Pathol 1995; 147:1567-1574.
112. 112 Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res 1990; 57:155-162.
113. 113 Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989; 339:303-305.
114. 114 Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989; 339:301-303.
115. 115 Hajjar KA, Nachman RL. The role of lipoprotein(a) in atherogenesis and thrombosis. Ann Rev Med 1996; 47:423-442.
116. 2 modification enhances lipoprotein(a) binding to the subendothelial matrix. Thromb Haemost 1998; 79:640-648.
117. 117 Kojima S, Harpel PC, Rifkin DB. Lipoprotein(a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991; 113:1439-1445.
118. 118 Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth-factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 1994; 370:460-462.
119. 119 Dangas G, Mehran R, Harpel P, Sharma SK, Marcovina SM, Dube G, et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 1998; 32:2035-2042.
120. 120 Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocytemacrophages. J Biol Chem 1992; 267:4143-4151.
121. 121 Keesler GA, Gabel BR, Devlin CM, Koschinsky ML, Tabas I. The binding activity of the macrophage lipoprotein(a)/Apolipoprotein(a) receptor is induced by cholesterol via a post-translational mechanism and recognizes distinct kringle domains on apolipoprotein(a). J Biol Chem 1996; 271:32096-32104.
122. 122 Higazi AA-R, Lavi E, Bdeir K, Ulrich AM, Jamieson DG, Rader DJ, et al. Defensin stimulates the binding of lipoprotein(a) to human vascular endothelial and smooth muscle cells. Blood 1997; 12:4290-4298.
123. 123 Cushing GL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TMA, Guyton JR, et al. Quantitation and localization of apolipoproteins(a) and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 1989; 9:593-603.
124. 124 Wyne KL, Pathak K, Seabra MC, Hobbs HH. Expression of the VLDL receptor in endothelial cells. Arterioscler Thromb Vasc Biol 1996; 16:407-415.
125. 125 Papagrigorakis E, Illiopoulos D, Asimacopoulos PJ, Safi HJ, Weibaecher DJ, Ghazzaly KG, et al. Lipoprotein(a) in plasma, arterial wall, and thrombus from patients with aortic aneurysm. Clin Genet 1997; 52:262-271.
126. 126 Lou XJ, Boonmark NW, Horrigan FT, Degen JL, Lawn RM. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci U S A 1998; 95:12591-12595.
127. 127 Pepin JM, O'Neil JA, Hoff HF. Quantification of apo(a) and apoB in human atherosclerotic lesions. J Lipid Res 1991; 32:317-327.
128. 128 Armstrong VW, Harrach B, Robenek H, Helmhold M, Walli AK, Seidel D. Heterogeneity of human lipoprotein Lp(a): cytochemical and biochemical studies on the interaction of two Lp(a) species with the LDL receptor. J Lipid Res 1990; 31:429-441.
129. 129 Hoover-Plow J, Scocir P. Enzymatic and chemical modifications of lipoprotein(a) selectively alter its lysine-binding functions. Biochim Biophys Acta 1998; 1392:73-84.
130. 130 Scanu AM, Miles LA, Fless GM, Pfaffinger D, Eisenbart J, Jackson E, et al. Rhesus monkey lipoprotein(a) binds to lysine sepharose and U937 monocytoid cells less efficiently than human lipoprotein(a). J Clin Invest 1993; 91:283-291.
131. 131 Hughes SD, Lou XJ, Ighani S, Verstuyft J, Grainger DJ, Lawn RM, Rubin EM. Lipoprotein(a) vascular accumulation in mice. J Clin Invest 1997; 100:1493-1500.
132. 132 Scanu AM, Pfaffinger D, Lee JC, Hinman J. A single point mutation (Trp72-Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a). Biochim Biophys Acta 1994; 1227:41-45.
133. 133 Laplaud PM, Beaubatie L, Rall SC, Luc G Jr, Saboureau M. Lipoprotein(a) is the major apoB-containing lipoprotein in the plasma of a hibernator, the hedgehog (Erinaceus europaeus). J Lipid Res 1998; 29:1157-1170.
134. 134 Makino K, Abe A, Maeda S, Noma A, Kawade M, Takenaka O. Lipoprotein(a) in nonhuman primates: presence and characteristics of Lp(a) immunoreactive materials using anti-human Lp(a) serum. Atherosclerosis 1989; 78:81-85.
135. 135 Lawn RM, Boonmark NW, Schwartz K, Lindahl GE, Wade DP, Byrne CD. The recurring evolution of lipoprotein(a). J Biol Chem 1995; 270:24004-24009.
136. 136 Chenivesse X, Huby Y, Wickins J, Chapman J, Thillet J. Molecular cloning of the cDNA encoding the carboxy-terminal domain of chimpanzee apolipoprotein(a): an Asp57-Asn mutation in kringle IV-10 is associated with poor fibrin binding. Biochemistry 1998; 37:7213-7223.
137. 137 Tomlinson JE, McLean JW, Lawn RM. Rhesus monkey apolipoprotein(a): Sequence, evolution, and sites of synthesis. J Biol Chem 1989; 264: 5957-5965.
138. 138 Brown MS, Goldstein JL. Teaching old dogmas new tricks. Nature 1987; 330:113-114.
139. 139 Yano Y, Shimokawa K, Okada Y, Noma A. Immunolocalization of lipoprotein(a) in wounded tissues. J Histochem Cytochem 1997; 45:559-568.
140. 140 Nachman RL. Thrombosis and atherogenesis: molecular connections. Circulation 1992; 96:2485-2487.
141. 141 O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal A, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79:315-328.
142. 142 Ribatti D, Vacca A, Giacchetta F, Cesaretti S, Anichini M, Roncali L, Damacco F. Lipoprotein(a) induces angiogenesis on the click embryo chorioallantoic membrane. Eur J Clin Invest 1998; 28:533-537.
143. 143 Lou XJ, Kwan HH, Prionas SD, Yang ZJ, Lawn RM, Fajardo LF. Despite its homology to angiostatin apolipoprotein(a) does not affect angiogenesis. Exp Mol Pathol 1998; 65:53-63.
144. 144 Syrovets T, Thillet J, Chapman MJ, Simmet T. Lipoprotein(a) is a potent chemoattractant for human peripheral monocytes. Blood 1997; 90:2027-2036.
145. 145 Poon M, Zhang X, Dunsky KG, Taubman MB, Harpel PC. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 1997; 96:2514-2519.
146. 146 Blencowe C, Hermetter A, Kostner GM, Deigner HP. Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein(a) in comparison with low density lipoprotein. J Biol Chem 1995; 270:31151-31157.
147. 147 Gorges R, Hofer G, Sommer A, Stütz H, Grillhofer H, Kostner GM, et al. Transfer of phospholipase A-resistant pyrene-dialkyl-glycerophosphocholine to plasma lipoproteins: differences between Lp(a) and LDL. J Lipid Res 1995; 36:251-259.
148. 148 Kochl S, Fresser F, Lobentanz E, Baier G, Utermann G. Novel interactin of apolipoprotein(a) with beta-2 glycoprotein I mediated by the kringle IV domain. Blood 1997; 90:1482-1489.
149. 149 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoproteinH). Proc Natl Acad Sci U S A 1990; 87:4120-4124.
150. 150 Phillips ML, Lembertas AV, Schumaker VN, Lawn RM, Shire SJ, Zioncheck TF. Physical properties of recombinant apolipoprotein(a) and its association with LDL to form an Lp(a)-like complex. Biochem 1993; 32:3722-3728.
151. 151 Baggio G, Donazzan S, Monti D, Mari D, Martini S, Gabelli C, et al. Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors. FASEB J 1998; 12: 433-437.
152. 152 Thillet J, Doucet C, Chapman J, Herbeth B, Cohen D, Faure-Delanef L. Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity evidence from a large population of French centenarians. Arthero 1997; 136:389-394.